• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Praxis Precision Medicines, Inc. - Common Stock (NQ:PRAX)

350.56 +14.95 (+4.45%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 286,383
Open 329.96
Bid (Size) 305.82 (40)
Ask (Size) 360.00 (80)
Prev. Close 335.61
Today's Range 329.96 - 352.73
52wk Range 35.21 - 358.76
Shares Outstanding 44,712,538
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline ↗
Today 17:51 EDT
Bright Minds Biosciences develops serotonin-based therapeutics for neurological and neuropsychiatric conditions in a pre-clinical model. 
Via The Motley Fool
Topics Intellectual Property Regulatory Compliance
News headline image
Why This Fund Added $12 Million to a Biotech Stock That's Now Down 58% in a Year ↗
Today 17:39 EDT
ADMA Biologics develops plasma-derived therapies for immune deficiencies and infectious diseases, leveraging a vertically integrated model. 
Via The Motley Fool
Topics Economy Regulatory Compliance

Performance

YTD
+22.4%
+22.4%
1 Month
+2.9%
+2.9%
3 Month
+5.7%
+5.7%
6 Month
+113.6%
+113.6%
1 Year
+830.4%
+830.4%

More News

Read More
News headline image
Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares ↗
May 17, 2026
Via The Motley Fool
Praxis Precision Medicines (NASDAQ:PRAX) Beats Q1 Estimates as FDA Accepts Two Key Drug Applications ↗
May 07, 2026
Via Chartmill
News headline image
Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares ↗
May 17, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million ↗
May 17, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million ↗
May 17, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter ↗
May 17, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally ↗
May 17, 2026
Via The Motley Fool
News headline image
Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More ↗
May 17, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy ↗
May 16, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Praxis (PRAX) Q1 2026 Earnings Call Transcript ↗
May 12, 2026
Via The Motley Fool
Topics Earnings
News headline image
Praxis Precision Medicines Q1 Earnings Call Highlights ↗
May 08, 2026
Via MarketBeat
Topics Earnings
News headline image
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results
May 07, 2026
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 05, 2026
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference
May 04, 2026
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor
April 14, 2026
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis to Showcase Essential3, the First Positive Phase 3 Program in Essential Tremor, at AAN 2026
April 13, 2026
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy
April 06, 2026
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 02, 2026
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs
March 30, 2026
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges ↗
March 22, 2026
Via The Motley Fool
News headline image
Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit ↗
March 18, 2026
Via The Motley Fool
News headline image
This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know? ↗
March 16, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal ↗
March 16, 2026
Via The Motley Fool
Topics Regulatory Compliance

Frequently Asked Questions

Is Praxis Precision Medicines, Inc. - Common Stock publicly traded?
Yes, Praxis Precision Medicines, Inc. - Common Stock is publicly traded.
What exchange does Praxis Precision Medicines, Inc. - Common Stock trade on?
Praxis Precision Medicines, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Praxis Precision Medicines, Inc. - Common Stock?
The ticker symbol for Praxis Precision Medicines, Inc. - Common Stock is PRAX on the Nasdaq Stock Market
What is the current price of Praxis Precision Medicines, Inc. - Common Stock?
The current price of Praxis Precision Medicines, Inc. - Common Stock is 350.56
When was Praxis Precision Medicines, Inc. - Common Stock last traded?
The last trade of Praxis Precision Medicines, Inc. - Common Stock was at 05/21/26 04:00 PM ET
What is the market capitalization of Praxis Precision Medicines, Inc. - Common Stock?
The market capitalization of Praxis Precision Medicines, Inc. - Common Stock is 15.67B
How many shares of Praxis Precision Medicines, Inc. - Common Stock are outstanding?
Praxis Precision Medicines, Inc. - Common Stock has 16B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap